Psychiatrische Universitätsklinik der Charité im St. Hedwig Krankenhaus
Berlin, 10115, Germany
NCT Number: NCT02576613
A randomized controlled, prospective, two-armed, mono-centric, assessor-blinded clinical trial will serve to generate preliminary data on the efficacy and safety of modified psychodynamic therapy (MPP-S) in stabilized patients after the first or subsequent episodes of schizophrenia or schizoaffective disorder.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Berlin, 10115, Germany
Rationale: Compared to the existing evidence for other psychotherapy methods like cognitive-behavioral psychotherapy or family interventions, the scientific basis of psychodynamic psychotherapy for psychoses is weak with respect to randomized-controlled research. Its encouragement by expert opinion and the broad application of this method stands in sharp contrast to the apparent lack of research interest regarding its efficacy and safety and the fact that more people suffering from schizophrenic spectrum disorders will hopefully embark on psychotherapy in the coming years.
The aim of the presented study is therefore on the one hand to explore the efficacy and safety of modified psychodynamic psychotherapy (MPP-S) in a randomized controlled study design. On the other hand, psychodynamic assumptions regarding the treatment of psychotic persons shall be elucidated in an explorative part of the study. For this purpose, a newly developed manual of modified psychodynamic psychotherapy for psychoses will be inaugurated.
Primary objective of the study is to determine whether the administration of MPP-S in addition to standard treatment (=treatment as usual: TAU) will lead to an improvement of psychosocial functioning in outpatients with schizophrenia and schizo-affective disorder compared to standard treatment.
Secondary objectives refer to the question, whether symptom domains and necessity of hospital treatment, as well as interpersonal functioning and subjective recovery might be impacted by MPP-S compared to TAU alone. Moreover, theoretical assumptions about possible psychodynamic mechanisms of action of MPP-S led to exploratory hypotheses, which are to be tested.
Safety and tolerability of the psychodynamic intervention will be evaluated by acquisition of safety data during study visits, but also by continuous monitoring of participants' condition after every treatment session and clinical contact.
Additional exploratory objectives of this study deal with the question, whether cerebral functional activity and connectivity within the so-called "Default-Mode-Network" (DMN) measured with fMRI are influenced by psychodynamic psychotherapy in the intervention group compared to the control condition. Moreover, changes of functional correlates of social cognition before and after psychotherapy or TAU will be compared between groups using a video-based social-cognitive task during fMRI.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
Other names: Modified psychodynamic psychotherapy
standard medical treatment without structured psychotherapeutic intervention
Other names: treatment as usual
Time frame: 6 months
Primary endpoint is the Mini-ICF-APP (=Mini-International Classification of Functioning for limitations of Activities and Participation in Psychological disorders) as a measure of disorders of capacity as defined by the International Classification of Functioning
Time frame: 12 months
Primary endpoint is the Mini-ICF-APP (=Mini-International Classification of Functioning for limitations of Activities and Participation in Psychological disorders) as a measure of disorders of capacity as defined by the International Classification of Functioning
Time frame: 24 months
Primary endpoint is the Mini-ICF-APP (=Mini-International Classification of Functioning for limitations of Activities and Participation in Psychological disorders) as a measure of disorders of capacity as defined by the International Classification of Functioning
Time frame: 36 months
Primary endpoint is the Mini-ICF-APP (=Mini-International Classification of Functioning for limitations of Activities and Participation in Psychological disorders)
Time frame: 6 months
psychotic symptoms measured by Positive and Negative Syndrome Scale (PANSS)
Time frame: 12 months
psychotic symptoms measured by Positive and Negative Syndrome Scale (PANSS)
Time frame: 24 months
psychotic symptoms measured by Positive and Negative Syndrome Scale (PANSS)
Time frame: 36 months
psychotic symptoms measured by Positive and Negative Syndrome Scale (PANSS)
Time frame: 6 months
depressive symptoms measured by Calgary Depression Scale for Schizophrenia
Time frame: 12 months
depressive symptoms measured by Calgary Depression Scale for Schizophrenia
Time frame: 24 months
depressive symptoms measured by Calgary Depression Scale for Schizophrenia
Time frame: 36 months
depressive symptoms measured by Calgary Depression Scale for Schizophrenia
Time frame: 6 months
necessity of hospital (inpatient) treatment, measured cumulative days in hospital per year
Time frame: 12 months
necessity of hospital (inpatient) treatment, measured cumulative days in hospital per year
Time frame: 24 months
necessity of hospital (inpatient) treatment, measured cumulative days in hospital per year
Time frame: 36 months
necessity of hospital (inpatient) treatment, measured cumulative days in hospital per year
Time frame: 6 months
Clinical Global Impression (CGI Severity und Improvement)
Time frame: 12 months
Clinical Global Impression (CGI Severity und Improvement)
Time frame: 24 months
Clinical Global Impression (CGI Severity und Improvement)
Time frame: 36 months
Clinical Global Impression (CGI Severity und Improvement)
Time frame: 6 months
Axes II-VI (relationships, conflicts, structure) of the Operationalized Psychodynamic Diagnostics (OPD)
Time frame: 12 months
Axes II-VI (relationships, conflicts, structure) of the Operationalized Psychodynamic Diagnostics (OPD)
Time frame: 24 months
Axes II-VI (relationships, conflicts, structure) of the Operationalized Psychodynamic Diagnostics (OPD)
Time frame: 36 months
Axes II-VI (relationships, conflicts, structure) of the Operationalized Psychodynamic Diagnostics (OPD)
Time frame: 6 months
Metacognition Assessment Scale-Abbreviated (MAS-A)
Time frame: 12 months
Metacognition Assessment Scale-Abbreviated (MAS-A)
Time frame: 24 months
Metacognition Assessment Scale-Abbreviated (MAS-A)
Time frame: 36 months
Metacognition Assessment Scale-Abbreviated (MAS-A)
Time frame: baseline
Movie for the Assessment of Social Cognition (MASC)
Time frame: 12 months
Movie for the Assessment of Social Cognition (MASC)
Time frame: 6 months
Levels of Emotional Awareness Scale (LEAS)
Time frame: 12 months
Levels of Emotional Awareness Scale (LEAS)
Time frame: 24 months
Levels of Emotional Awareness Scale (LEAS)
Time frame: 6 months
Inventory of Interpersonal Problems (IIP-D)
Time frame: 12 months
Inventory of Interpersonal Problems (IIP-D)
Time frame: 24 months
Inventory of Interpersonal Problems (IIP-D)
Time frame: 36 months
Inventory of Interpersonal Problems (IIP-D)
Time frame: 6 months
Questionnaire to assess subjective meaning in psychosis (SuSi)
Time frame: 12 months
Questionnaire to assess subjective meaning in psychosis (SuSi)
Time frame: 24 months
Questionnaire to assess subjective meaning in psychosis (SuSi)
Time frame: 36 months
Questionnaire to assess subjective meaning in psychosis (SuSi)
Time frame: baseline
BOLD-contrast, structure
Time frame: 24 months
BOLD-contrast, structure
Charite University, Berlin, Germany
Other
Modified Psychodynamic Psychotherapy for Patients With Schizophrenia - a Randomized Controlled Trial
Acronym: MPP-S
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01945333
Mental Disorders, Psychotic Disorders
Brooklyn, New York, United States
View Trial DetailsNCT00001486
Behavior, Behavioral Symptoms
Bethesda, Maryland, United States
View Trial DetailsNCT00942981
Mental Disorders, Psychotic Disorders
Bethesda, Maryland, United States
View Trial DetailsNCT06007105
Acute and Transient Psychotic Disorder, Bipolar Type I Disorder With Psychotic Symptoms
Blantyre, Southern Region, Malawi
View Trial Details